13F Filings: Superstar Investor Buys and Sells
With another May comes another quarterly disclosure of the holdings of institutional money managers with assets of at least $100 million. The Securities & Exchange Commission (SEC) requires these managers to report their stock holdings via Schedule 13F within 45 days of the end of each quarter.
In February, when these investors last updated their holdings (as of the end of the fourth quarter of 2012), we highlighted four picks from each of four different investment gurus—Seth Klarman, David Einhorn, Julian Robertson and Daniel Loeb—to see what they can tell us about which stocks may be moving up—or down.
In that article, we discussed Seth Klarman’s new position in American International Group (NYSE: AIG). Since that article came out on February 20, AIG has soared from $37.57 to today’s level of $44.96—for a 19.7% gain in just three months.
These updates also give us a chance to stack these investment pros up against one another and see how their picks compare.
In the last three months, only eight of the 16 stocks highlighted (50%) in our February article made a profit (a sold stock is considered profitable if it went down in price). Making a profit is different from outperforming a stock index, however. Of the 10 stocks the gurus bought in the fourth quarter, six (60%) have beaten the S&P’s return of 10.0% in the past three months. Of the six stocks sold, two (33%) underperformed the S&P 500, so the gurus were better bulls than bears.
In addition to American International Group, “buy” winners included David Einhorn’s Microsoft (NasdaqGS: MSFT) (+25.0%) and Cigna (NYSE: CI) (+14.0%); Julian Robertson’s Berkshire Hathaway (NYSE: BRK.B) (+12.5%); and Daniel Loeb’s News Corp. (NasdaqGS: NWSA) (+15.7%) and Herbalife (NYSE: HLF) (+33.8%).
Losing trades included Julian Robertson’s new position in ADT Corp. (NYSE: ADT), which has plunged 10.6% in the last three months. On the sell side, Seth Klarman missed out on a big gain by getting out of Hewlett-Packard (NYSE: HPQ), which has risen 26.4%, and David Einhorn is likely regretting cutting back on Seagate Technology (NasdaqGS: STX), which has soared 27.8%.
In all, the four gurus invested their way to a draw, with each posting two winning trades out of four (winning trades being buys that outperformed the S&P 500 or sells that went on to be outpaced by the benchmark index.)
Miscues like the ones mentioned above illustrate how important it is to do your own research and not merely follow the actions of investment pros, no matter how distinguished they may be; in addition, it’s important to keep in mind that these 13F filings are usually out of date by the time they are released and likely don’t paint an up-to-the-minute picture of each investor’s holdings.
Nevertheless, they are still a gold mine of information as to what the smartest investors are buying and selling. A timely review of them can make you money. With that in mind, here are some highlights from all four investors’ just-released 13F filings.
Note that the following is not a full account of these gurus’ transactions, just a few that are worth noting. If you’re keen to see what picks the cream of the investment crop are making these days (and who isn’t?), read on.
1. Seth Klarman |
||||
Company |
Action |
% Change in Holding |
Average Purchase Price Per Share |
Comments |
Elan Corp. (NYSE: ELN) |
Buy |
NEW |
$10.70 |
An Ireland-based biotech firm that’s working on treatments for neurological conditions like Alzheimer’s, MS and Parkinson’s. |
Directv (NasdaqGS: DTV) |
Buy |
NEW |
$52.51 |
The satellite TV provider’s shares have soared 30% since the beginning of the year. Klarman’s betting they have plenty of room to run yet. |
News Corp. (NasdaqGS: NWSA) |
Sell |
-100% |
$28.41 |
Klarman closes out his position after the stock posts a 55% gain from the end of Q1 2012 to March 29, 2013. |
Idenix Pharmaceuticals (NasdaqGS: IDIX) |
Buy |
25.8% |
$4.45 |
Klarman adds to his holdings in the hepatitis C drug company for the eighth straight quarter. |
2. David Einhorn |
||||
Company |
Action |
% Change in Holding |
Average Purchase Price Per Share |
Comments |
Microsoft (NasdaqGS: MSFT) |
Sell |
-43.9% |
$27.54 |
The software giant is redesigning its Windows 8 operating system after a disappointing launch. |
Apple (NasdaqGS: AAPL) |
Buy |
83.5% |
$468.78 |
Einhorn ups his position as Apple hikes its dividend and expands its buyback program; he had been pressuring the company to do just that. |
Delphi Automotive (NYSE: DLPH) |
Sell |
-25.0% |
$41.07 |
Einhorn takes profits after the auto-parts maker’s shares surge 128% since the end of 2011. |
Computer Sciences Corp. (NYSE: CSC) |
Sell |
-23.3% |
$90.88 |
Another winner for Einhorn, Computer Sciences has risen 38% since the end of Q3 2012, when he took his initial position. |
3. Julian Robertson |
||||
Company |
Action |
% Change in Holding |
Average Purchase Price Per Share |
Comments |
Apple (NasdaqGS: AAPL) |
Sell |
-100% |
$468.78 |
Robertson joins other investors heading for the exits on concerns about slowing demand and cutthroat competition in the tablet and smartphone markets. |
Moody’s Corp. (NYSE: MCO) |
Buy |
NEW |
$49.36 |
The rating agency’s shares have been on the rise since it settled a lawsuit related to the financial crisis on April 29. |
McGraw-Hill Financial (NYSE: MHFI) |
Buy |
NEW |
$50.51 |
The company, which owns Standard & Poor’s, has also benefited from the lawsuit settlement. However, it still faces a $5-billion suit filed by the Justice Department. |
H&R Block (NYSE: HRB) |
Buy |
NEW |
$24.24 |
After languishing since early 2010, the tax-preparer’s stock has come back to life, doubling in the past 12 months. Its 2.7% dividend yield is also attractive. |
4. Daniel Loeb |
||||
Company |
Action |
% Change in Holding |
Average Purchase Price Per Share |
Comments |
Abbvie (NYSE: ABBV) |
Buy |
609% |
$37.25 |
Abbott Labs completed the spinoff of Abbvie on January 1, 2013. It produces treatments for a wide range of conditions, including HIV, cystic fibrosis and thyroid disease. |
Anadarko Petroleum (NYSE: APC) |
Buy |
NEW |
$82.47 |
Shares have moved up since April 19, the day after the company announced a significant natural gas discovery off Mozambique |
Herbalife (NYSE: HLF) |
Sell |
-100% |
$39.20 |
Loeb closes out his holding after he joined Carl Icahn by going long on the supplement maker after Bill Ackman revealed his 20-million-share short position. |
Morgan Stanley (NYSE: MS) |
Sell |
-100% |
$21.97 |
Loeb’s Third Point LLC said it bought in at an average cost of $16.77 a share when it announced its Morgan Stanley stake in January. The stock now trades at around $25. |